Tx Medic Ab

Anders Waas

Lars M Bruce

Adam Bruce

Ida Duprez

The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Use of dextran sulfate

Use of dextran sulfate having an average molecular weight below 10000 DA for inducing angiogenesis in a subject

The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.

Dextran sulfate in a range of 3500 and 9500 Da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration.

Growing community of inventors

Göteborg, Sweden

Anders Waas